Home / People / Dr. Thomas Hirse
Portrait ofThomas Hirse

Dr. Thomas Hirse

Partner
Rechtsanwalt

CMS Hasche Sigle
Kasernenstraße 43-45
40213 Duesseldorf
Germany
Languages German, English

Thomas Hirse has extensive experience in patent and utility model law, including all related antitrust law aspects and questions related to employee inventions. In addition, he is specialized on trade secret protection and data protection law specific for life sciences and medical devices companies.

He regularly advises on technology-driven mergers and acquisitions as well as patent litigation matters particularly in the life sciences and medical devices sector as well as plant engineering and construction industry. He has extensive experience with the legal evaluation and enforcement of intellectual property, including development of IP protection concepts and strategy. Additionally, Thomas successfully drafted and negotiated numerous complex R&D and license agreements and handled IP-related issues in R&D and licensing collaborations for his clients, including related competition law and public funding and subsidy law aspects.

Thomas advises and represents clients in national and international patent disputes with respect to both enforcement of their patents and the defense of patent infringement actions, including representation in opposition, invalidation and cancellation proceedings. He regularly provides patent FTO-analyses.

He started his legal career with Linklaters in 2006, joined CMS in 2007 and was seconded to Bayer in 2010 and a global specialty chemical enterprise in 2013. He has been a partner since 2014.

Thomas is member of GRUR, LES, AIPLA, EPLAW, the Advisory Board of the Research Alliance Leibniz Health Technologies, Co-Head of the working group "IP and technology agreements" and active member of the working group "Technology transfer" of the German biotech association BIO Deutschland e.V.

more less

Publications

  • Schriftenreihe des Max-Planck-Instituts für auslaendisches und internationales Privatrecht, Die Ausweichklausel im Internationalen Privatrecht - Methodentheoretische und -kritische Gedanken zu einer besonderen kollisionsrechtlichen Generalklausel, Mohr Siebeck Tübingen 2007
  • Kothe/Micklitz/Rott/Tonner/Willingmann; Das neue Schuldrecht - Kompaktkommentar, Kommentierung der Regelungen zum Leistungsstoerungs-und Ruecktrittsfolgenrecht, Luchterhand 2003
  • Beitraege zur Neuregelung des Leistungsstoerungsrechts im Rahmen der Schuldrechtsmodernisierung, VuR 2001, p. 99 ff
  • Die Prozessfuehrung durch den Versicherer (zus. mit Prof. Dr. Harald Koch), VersR 2001
  • Anmerkungen und Beitraege zu verschiedenen BGH-Entscheidungen zum Folgekostenstreit bei straßenbaubedingter Verlegung von Versorgungsleitungen in den neuen Bundeslaendern, NJ 2001, p. 459 ff
more less

Education

  • 2005: PhD; thesis on international private law
  • 2003 - 2005: Trainee lawyer at Wuppertal Regional Court
  • 2001 - 2002: Friedrich Naumann Foundation PhD scholar
  • 2001 - 2002: Worked as legal expert for Arbeitsgemeinschaft der Verbraucherverbände e.V. in the context of the legislative process for the reform of the German law of obligations
  • 2000 - 2002: Research assistant to a Higher Regional Court judge and to Prof. Dr. Harald Koch, Chair for Civil Law, Civil Procedure Law, International Private Law and Comparative Law
  • 1995 - 2000: Law studies at the University of Rostock
more less

Feed

28/02/2024
CMS advises Bruker on the multi-jur­is­dic­tion­al acquisition of ELITech,...
Frankfurt/Main – Bruker has agreed to acquire ELITechGroup, a provider of specialty in vitro diagnostic (IVD) systems, from TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, for EUR 870 million in cash, excluding the carved out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals and other customary closing conditions.A team of CMS Germany headed by lead partner Dr Hendrik Hirsch acted as lead transaction counsel on this landmark transaction for Bruker's MDx business covering all M&A aspects of the transaction, IVDR and other regulatory aspects, antitrust and FDI filings, the carve out of the clinical chemistry business and support on the employee consultation processes in France and the Netherlands. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and Be-Genius® in the mid-to-high throughput MDx category with PCR diagnostic assays for infections and diseases. ELITechGroup, excluding the clinical chemistry business, achieved approximately EUR 150 million in revenues in 2023. ELITechGroup generates the majority of its revenues from Europe, with significant business also in North and Latin America. Its major R&D and production sites are in Italy, the United States, France and Germany. CMS Germany Dr Hendrik Hirsch, Partner, Co-Lead Dr Jacob Siebert, Partner, Co-Lead Dr Dirk Baukholt, Principal Counsel Dr Berrit Roth-Mingram, Counsel Dr Maximilian Stark, Senior Associate, all Corporate/M&A Dr Roland Wiring, Partner Lukas Burgdorff, Associate Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Thomas Hirse, Part­ner Se­basti­an Vautz, Senior Associate Lisa Dietrich, Associate, all IP Dr Michael Bauer, Partner Stefan Lehr, Partner Kai Neuhaus, Partner Moritz Pottek, Counsel Dr. Denis Schlimpert, Counsel Kirsten Baubkus-Gerard, Senior Associate David Rappenglück, As­so­ci­ate Be­ne­dikt Christian Voss, Associate, all Antitrust, Competition & Trade Dr Thomas de la Motte, Partner Dr Markus Pfaff, Partner Dr André Frischemeier, Partner Hatice Aykel, Counsel Alisa Brehm, Senior Associate Thomas Schaak, Senior Associate Dr Sait Dogan, Associate, all Banking & Finance  Dr André Lippert, Part­ner Con­stan­ze Schweidtmann, Associate, both Real Estate & Public Dr Boris Alles, Partner Dr Theresa Kipp, Senior Associate, both Labor, Employment & Pensions CMS France Benoît Gomel, Partner Vincent Desbenoit, Associate Dylan Allali, all Corporate/M&A Caroline Froger-Michon, Partner Aurélie Parchet, As­so­ci­ate Ca­m­ille Baumgarten, Associate Sophie Yin, all Em­ploy­ment Claire Vannini, Partner Eleni Moraïtou, Coun­sel Lilia-Ori­ana Dif, Associate Ariane Rolin, all Competition & EU  Jean-Bap­tiste Thiénot, Partner Anaïs Arnal, Associate, both Intellectual Property Laurine Mayer, Associate, TMC Alexandre Chazot, Counsel, Banking & Fin­ance  Thi­erry Granier, Partner Renaud Grob, Partner, both Tax Arnaud Valverde, Senior Associate, Real Estate Olivier Kuhn, Partner Cécile Rebiffé, Counsel Mylène Garrouste, all Dispute Res­ol­u­tion Kawthar Ben Khelil, Coun­sel Jean-Pierre Malili, Associate, both Public law/In­fra­struc­ture CMS Italy Massimo Trentino, Partner, Corporate/M&A Maria Letizia Patania, Partner, Lifescience & Healthcare Gian Marco Lettieri, Senior Associate, Employment & Pensions Giulio Poggioli, Counsel Valerio Giuseppe Daniele, As­so­ci­ate Francesca Durante, Junior As­so­ci­ate  Arianna Toccaceli, Junior Associate, all Banking & Finance CMS Luxembourg Gérard Maitrejean, Partner Miruna Poenaru, Coun­sel Max­imili­an Helfgen, Associate, all Corporate/M&A CMS UK Jack Letson, Partner Lindsay McAllister, Associate, both Corporate/M&A David Dennis, Partner, Commercial CMS Netherlands Pieter van Duijvenvoorde, Partner Robert Jong, both Corporate/M&A Nigel Henssen Fleur van Assendelft de Coningh, both Employment Edmon Oude Elferink, Partner Marijke van der Vossen, both Antitrust, Competition & Trade CMS Serbia Radivoje Petrikić, Partner Mila Drljević, both Corporate/M&A CMS Austria Dieter Zandler, Partner Vanessa Horaceck, both Competition & EU CMS Ukraine Maria Orlyk, Partner Diana Valyeyeva CMS Turkiye Döne Yalçın, Partner Arcan Kemahlı,  Sa­ba­hat­tin Öztemiz Taner ElmasPress Con­tact presse@cms-hs. com
01/02/2024
Early days of the UPC - key issues and take-aways
 
16/11/2023
On the Pulse Webinar Series 2023 - Autumn
On the Pulse webinar series brings you updates on the latest legal and commercial developments in the life sciences & healthcare sector. The Autumn edition will see our CMS sector specialists cover: Commercial - Deal landscape and transaction trends in the Life Sciences SectorDispute Resolution - The midnight clause: why choice of law and jurisdiction clauses matterPublic Procurement - Typical pitfalls to be avoided in a procurement process for pharma and medical devices suppliesequIP - Pitfalls for life sciences start-ups to avoidEach webinar will be one hour in length with a 15-minute Q&A session. To register for the full series or just the topics of interest to you, click on the registration links below. To watch the Spring webinars in the On the Pulse series, visit here.
14/11/2023
Seed financing: CMS advises Brandenburg Kapital on investment in Seqstant
Berlin – Seqstant has successfully completed a seed financing round led by Brandenburg Kapital, the venture capital unit of the Investitionsbank des Landes Brandenburg. Other investors include the Venture...
11/10/2023
CMS advises US technology company Bruker on entering into equity-based...
Frankfurt/Main – Bruker Corporation, a NASDAQ-listed US tech company, has acquired a majority stake in MIRO Analytical AG, an innovative provider of fast, compact Quantum Cascade Laser (QCL)-based multi-gas...
13/06/2023
CMS advises fund managed by private equity firm ECM on acquisition of ONE...
Frankfurt/Main – German Equity Partners V (“GEP V” or the “Fund”) has taken an equity interest in the Düs­sel­dorf-based talent acquisition platform ONE HIRING Group (“1H”) through a partnership...
08/05/2023
CMS advises US technology company Bruker on acquisition of ZONTAL to further...
Frankfurt/Main – Bruker Corporation, a NASDAQ-listed US tech company, has acquired a majority stake in the ZONTAL Group. Based in Germany, the US and China, ZONTAL is a leading provider of data platforms...
05/04/2023
CMS advises Extantia on EUR 6.3 million seed financing round for climatetech...
Berlin – Climatetech start-up Magnotherm, a producer of innovative refrigerators that are cooled using magnetic fields, has successfully completed a seed round of financing worth EUR 6.3 million. The...
23/03/2023
On the Pulse webinar series 2023 - Spring
Welcome to the launch of the On the Pulse webinar series
28/02/2023
CMS advises European greentech venture Gauss Fusion on EUR 8 million pre-seed...
Frankfurt/Main – Gauss Fusion GmbH, a green venture in the fusion technology sector based in Hanau, has raised around EUR 8 million in an initial pre-seed round of financing. Gauss Fusion is an initiative...
17/02/2023
CMS advises DPE Deutsche Private Equity on sale of VTU Group to Altor Funds
Frankfurt/Main – Funds advised by DPE Deutsche Private Equity have sold the VTU Group to Altor Funds, with the VTU management team likewise selling its interest in the company. DPE is an independent...
09/02/2023
CMS advises private equity firm Pinova Capital on acquisition of Riepe
Frankfurt/Main – Funds advised by Pinova Capital, an independent private equity firm focusing on high-growth SMEs, have acquired Riepe GmbH & Co. KG from the owners, the Riepe family, by way of a management...